EGFR and non-small cell lung carcinoma: In conclusion, the findings of the present study suggest that a portion of patients with advanced NSCLC with low NLR characteristics (NLR ≤ 4), even those harboring EGFR-sensitive mutations, could benefit from anti-PD-1 inhibitors as further line treatment after progression to EGFR-TKIs.